Arcus Biosciences, Inc.
RCUS
$19.72
-$0.47-2.33%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -46.74% | 100.00% | -2,700.00% | -16.05% | -29.58% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.00% | -18.75% | -61.11% | 0.00% | -6.25% |
| Change in Net Operating Assets | -79.21% | -678.95% | 0.00% | 4.17% | 1,222.22% |
| Cash from Operations | -473.08% | -41.49% | -6,500.00% | -13.64% | 141.27% |
| Capital Expenditure | 100.00% | -- | 75.00% | 83.33% | 90.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 382.14% | 117.46% | 120.00% | 52.94% | -233.33% |
| Cash from Investing | 372.41% | 117.46% | 118.93% | 82.14% | -363.64% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 300.00% | 0.00% | -37.99% | 0.00% | -66.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -83.33% | 2,500.00% | -37.99% | -166.67% | 700.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -122.22% | 293.10% | -27.59% | 10.53% | 197.83% |